Bristol Myers Squibb, Princeton, NJ 08540, USA.
HealthCore, Inc., Wilmington, DE 19801, USA.
Future Oncol. 2021 Jan;17(3):291-299. doi: 10.2217/fon-2020-0516. Epub 2020 Sep 30.
Study first-line (1L) treatment patterns and economic outcomes among patients with advanced metastatic gastric cancer (GC) and esophageal cancer (EC). Newly diagnosed patients with systemic GC and EC treatments were identified between 1 January 2011 and 31 July 2017; costs were presented as per patient per month (PPPM) basis. Study included 392 GC and 436 EC patients. Most frequently used 1L regimens were: 5-fluorouracil (5-FU) + oxaliplatin (22.5%) and epirubicin + cisplatin + 5-FU (ECF)/ECF modifications (21.9%) in patients with GC; and carboplatin + paclitaxel (29.6%) and 5-FU + oxaliplatin (11.5%) in EC patients. Mean all-cause costs were US$16,242 PPPM for GC, and $18,384 PPPM for EC during 1L treatment. GC and EC were resource intensive and costly. High costs and short treatment durations underscored a gap in care in 1L treatment.
研究初治（1L）转移性晚期胃癌（GC）和食管癌（EC）患者的治疗模式和经济结果。2011 年 1 月 1 日至 2017 年 7 月 31 日期间，确定了新诊断为全身 GC 和 EC 治疗的患者；费用以每位患者每月（PPPM）为基础计算。研究包括 392 例 GC 和 436 例 EC 患者。GC 患者中最常使用的 1L 方案是：5-氟尿嘧啶（5-FU）+奥沙利铂（22.5%）和表柔比星+顺铂+5-FU（ECF）/ECF 改良（21.9%）；EC 患者中最常使用的方案是卡铂+紫杉醇（29.6%）和 5-FU+奥沙利铂（11.5%）。1L 治疗期间，GC 的全因费用平均为 16242 美元/PPPM，EC 的全因费用平均为 18384 美元/PPPM。GC 和 EC 资源消耗大，费用高。高成本和短治疗持续时间突出了 1L 治疗中护理方面的差距。
